Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 to 68 years of age~* Confirmed diagnosis of Multiple Sclerosis~* Clinical history of pseudobulbar affect~Exclusion Criteria:~* Sensitivity to quinidine or opiate drugs~* Recent diagnosed within 2 months with Multiple Sclerosis~* Patient on anti-depressants~* Patient with liver or kidney disease~* Patient with hypotension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).